Drug Profile

DS 2325a

Alternative Names: DS-2325; DS-2325a

Latest Information Update: 31 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daiichi Sankyo Inc
Class Gene therapies; Skin disorder therapies
Mechanism of Action Gene transference; Kallikrein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Netherton Syndrome
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase I/II Netherton Syndrome

Most Recent Events

20 Jan 2025 Daiichi Sankyo terminates the Phase-I/II clinical trials in Netherton-Syndrome in France (SC) (IV) based on a business decision by the Sponsor (NCT05979831)
28 Sep 2023 Phase-I/II clinical trials in Netherton-Syndrome in France (IV) (NCT05979831)
28 Sep 2023 Phase-I/II clinical trials in Netherton-Syndrome in France (SC) (NCT05979831)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com